Cis-aconitate therapy protects against influenza mortality by dual targeting of viral polymerase and ERK/AKT/NF-κB signaling

Abstract The influenza virus poses a significant global health challenge, causing approximately 500,000 deaths annually. Its ability to evade antiviral treatments and vaccine-induced immunity underscores the need for novel therapeutic approaches. Our study identifies cis-aconitate (cis-aco), a mitoc...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Adeline Cezard, Déborah Brea-Diakite, Virginie Vasseur, Alan Wacquiez, Loic Gonzalez, Ronan Le Goffic, Bruno Da Costa, Ambre Tinard, Delphine Fouquenet, Séverine Heumel, Arnaud Machelart, Eik Hoffmann, Priscille Brodin, François Trottein, Cyrille Mathieu, Lola Canus, Florentine Jacolin, Pierre-Olivier Vidalain, Laure Perrin-Cocon, Vincent Lotteau, Julien Burlaud-Gaillard, Dominique Tertigas, Michael G Surette, Antoine Legras, Damien Sizaret, Thomas Baranek, Christophe Paget, Antoine Guillon, Mustapha Si-Tahar
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Springer Nature 2026-02-01
coleção:	EMBO Molecular Medicine
Assuntos:	Influenza Virus Therapy Antiviral Anti-inflammatory Pneumonia
Acesso em linha:	https://doi.org/10.1038/s44321-026-00379-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!